Atlas Trials

Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT06973330 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06973330
Sponsor
Anhui Provincial Cancer Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Start date
2025-07-01
Primary completion
2027-05-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.